BRD4 Degrader Compound via PROTAC Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that can inhibit or degrade bromodomains, particularly BRD4, to treat cancer, immunological conditions, and other bromodomain-related diseases, as mutations in these proteins are associated with various human dysfunctions and recent findings suggest transcriptional regulation as a potential therapeutic target.
Innovation Solution
A compound represented by formula (I) and its derivatives, including racemates, stereoisomers, and pharmaceutically acceptable salts, which selectively target and degrade BRD4 proteins, providing a pharmaceutical composition for the prevention and treatment of bromodomain-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibition of bromodomain is used, then transcriptional regulation is achieved for therapeutic potential, but the ability to effectively degrade BRD4 proteins is insufficient
Solution Approach 1:
The patent employs a proteolysis targeting chimera (PROTAC) molecule as an intermediary that bridges the BRD4 protein and the ubiquitin-proteasome degradation system. The PROTAC contains a bromodomain-binding module that targets BRD4, a linker module for structural flexibility, and a recruitment module that engages E3 ubiquitin ligase, thereby mediating targeted protein degradation through the cellular ubiquitin-proteasome pathway
Solution Approach 2:
The invention changes the mechanism of action from simple inhibition to active degradation by designing molecules with specific structural parameters including molecular weight (500-2000 Da), logP value (1-5), and containing specific functional groups (bromodomain-binding moiety, linker, and E3 ligase recruitment moiety). These parameter changes enable the compound to not only bind but also trigger degradation of BRD4
2Adaptability or versatility
If selective inhibition of bromodomains is pursued, then opportunities for novel therapeutic agents are created, but the complexity of achieving selective degradation increases
Solution Approach 1:
The PROTAC molecule is segmented into three distinct functional modules: (1) a bromodomain-binding module that selectively targets BRD4, (2) a linker module that provides structural flexibility and connects the two functional domains, and (3) a recruitment module that engages E3 ubiquitin ligase. This segmentation allows independent optimization of each module for selectivity and degradation efficiency
Solution Approach 2:
The invention utilizes the universal ubiquitin-proteasome degradation pathway as a multi-functional mechanism that can be harnessed for selective degradation of various bromodomain-containing proteins. By designing PROTACs with different bromodomain-binding modules, the same degradation mechanism can be applied to target multiple disease-relevant proteins, creating versatile therapeutic agents
3Reliability
If compounds targeting BRD4 are developed, then treatment of cancer and immunological conditions is enabled, but the manufacturing precision required for stereoisomers and salts increases
Solution Approach 1:
The patent performs preliminary stereochemical characterization and salt form selection during the drug discovery phase. The preferred enantiomer or diastereomer is identified and isolated early in development, and stable pharmaceutically acceptable salt forms are selected and characterized before clinical development begins. This preliminary action simplifies subsequent manufacturing by establishing clear specifications for stereoisomer purity and salt form control
Solution Approach 2:
The invention transforms the manufacturing challenge by changing the physical chemical parameters of the active compound through salt formation. By converting the PROTAC into stable salt forms with defined solubility and crystallization properties, the manufacturing process can achieve required purity levels through standard pharmaceutical techniques such as crystallization and filtration, rather than requiring complex chiral separation processes
Data Source
AI summary
A compound is represented by formula (I). The compound, a racemate, a stereoisomer, a tautomer, an isotopically labeled compound, a nitrogen oxide, a solvate, a polymorph, a metabolite, an ester, and a prodrug or a pharmaceutically acceptable salt thereof have relatively good BRD4 inhibition and degradation effects when used as a medicament, and can be used for manufacturing a medicament related to BRD4 inhibition and degradation and preventing and/or treating a related disease.